Video

Aurion BioTech presents cell therapy findings with published clinical data

Author(s):

Kassi Jackson
Conferences|ASCRS

Greg Kunst, president and CEO of Aurion BioTech, shares a company update on endothelial cell therapy trials, clinical plans and upcoming data.

Related Videos
4 experts are featured in this series.
Related Content
eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa
December 17th 2024

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Researchers awarded $2.7 million NIH grant to study retinal connections in RP
December 14th 2024

Researchers awarded $2.7 million NIH grant to study retinal connections in RP

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases
December 10th 2024

Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases

Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program
December 4th 2024

Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program

© 2024 MJH Life Sciences

All rights reserved.